The ADC (disitamab vedotin) targets HER2, is internalized, and releases MMAE, which binds beta-tubulin (vinca site) to block microtubule polymerization, causing G2/M arrest and apoptosis. Killing is driven by HER2-directed delivery (with possible bystander effect), not by tubulin expression per se.